INVA Innoviva, Inc.

NASDAQ
$19.24

Innoviva, Inc. (INVA) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is $0.48 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.6% since its last earnings release on November 4, 2026.

Innoviva Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.48
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $19.24

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Innoviva, Inc.

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Drug Manufacturers / Major

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.